Tarsus Pharmaceuticals (TARS) Total Debt (2022 - 2026)

Tarsus Pharmaceuticals' Total Debt history runs 5 years deep, the most recent figure standing at $72.6 million for Q1 2026.

• On a quarterly basis, Total Debt rose 0.85% year-over-year to $72.6 million in Q1 2026; TTM through Mar 2026 was $72.6 million, a 0.85% increase from a year earlier, with the FY2025 full-year figure at $72.4 million, up 0.83% from the prior year.
• Total Debt was little changed at $72.6 million in Q1 2026 per TARS's latest filing, from $72.4 million in the prior quarter.
• Across five years, Total Debt topped out at $72.6 million in Q1 2026 and bottomed at $19.2 million in Q1 2022.
• The 5-year median for Total Debt is $29.9 million (2024), against an average of $46.6 million.
• Across the five-year window, Total Debt surged 190.88% in 2024 and increased 0.77% in 2025, its largest moves.
• Year by year, Total Debt stood at $19.4 million in 2022, then soared by 53.44% to $29.8 million in 2023, then soared by 140.94% to $71.8 million in 2024, then rose by 0.83% to $72.4 million in 2025, then grew by 0.22% to $72.6 million in 2026.
• Per Business Quant, the three latest TARS Total Debt figures stand at $72.6 million (Q1 2026), $72.4 million (Q4 2025), and $72.3 million (Q3 2025).